www.fdanews.com/articles/159609-ema-accepts-file-for-astrazeneca-parp-inhibitor
EMA Accepts File for AstraZeneca PARP Inhibitor
October 1, 2013
The EMA has accepted a marketing authorization application from AstraZeneca for olaparib, a PARP inhibitor targeting BRCA-mutated platinum-sensitive serous ovarian cancer.
Pharma Times
Pharma Times